Feb 16 (Reuters) - CSL Ltd CSL.AX :
* will report loss in range of approximately US$90 - 120 million this financial year for Novartis Influenza Vaccines Business
* HY2016 results announcement and analyst briefing
* "Reconfirm my previous guidance for fy16 of 5% profit growth at constant currency"
* "Earnings per share growth for the group is expected to exceed profit growth"
* Source text for Eikon ID:nASX8ys17h